Loading…
Company plans to offer $250 million in common stock and reported trial success.
Rapport Therapeutics, Inc. announced on 2025-09-08 Rapport Therapeutics announced a proposed public offering of common stock and reported positive topline results from a Phase 2a clinical trial of RAP-219 in patients with focal onset seizures.
The announcement cited $250.0 million, $37.5 million, 77.8%, 24%, 85.2%, 72.0%, 71.0%, 10%, 26.7%, 16.7%, 13.3%, and 10.0%.
Rapport Therapeutics, Inc. has a free float of 30,421,600 shares and 47,661,100 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.